Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
Public ClinicalTrials.gov record NCT05275205. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (Wet AMD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Study identification
- NCT ID
- NCT05275205
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2022 (Actual)
- Primary completion
- Feb 15, 2023 (Actual)
- Completion
- Jul 25, 2023 (Actual)
- Last update posted
- Aug 7, 2024
2022 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Salehi Retina Institute | Huntington Beach | California | 92647 | — |
| Advanced Vision Research Institute | Longmont | Colorado | 80503 | — |
| Rand Eye Institute | Deerfield Beach | Florida | 33064 | — |
| Retina Vitreous Associates of Florida | St. Petersburg | Florida | 33711 | — |
| University Retina and Macula Associates | Lemont | Illinois | 60439 | — |
| Illinois Eye Center | Peoria | Illinois | 61615 | — |
| Midwest Eye | Carmel | Indiana | 46290 | — |
| Mayo Clinic-Rochester | Rochester | Minnesota | 55905 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| EyeHealth Northwest | Portland | Oregon | 97225 | — |
| Retina Research Institution of Texas | Abilene | Texas | 79606 | — |
| Valley Retina Institute | McAllen | Texas | 78503 | — |
| Austin Retina Associates | Round Rock | Texas | 78681 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05275205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05275205 live on ClinicalTrials.gov.